Agilent Sponsors the Nonprofit “My Green Lab”
Agilent Technologies, Inc. has become a sponsor of My Green Lab, a nonprofit organization dedicated to improving the sustainability of scientific research.
Agilent Technologies, Inc. (Santa Clara, California) has become a sponsor of My Green Lab, a nonprofit organization dedicated to improving the sustainability of scientific research.
Agilent chose to support My Green Lab because of its “holistic approach to sustainability and their understanding of the interconnectivity between all the parts that make up a laboratory-from chemicals to instruments to the environment,” according to the company.
“Sustainability is a key consideration in all our activities, and we look forward to ultimately passing on the benefits of our efforts and innovation to make better informed, sustainable choices”, said Mike McMullen, Agilent CEO.
Agilent is currently working with My Green Lab to have the company’s instruments independently audited for the organization’s Accountability, Consistency, and Transparency (ACT) label. The ACT label provides information about the environmental impact of manufacturing, using, and disposing of a product and its packaging.
“We are really excited to be working with Agilent,” My Green Lab CEO Allison Paradise said in a statement. “The fact that Agilent is willing to highlight sustainability through our ACT labelling program speaks to Agilent’s leadership in this area.”
Free Poster: NDSRI Risk Assessment and Trace-Level Analysis of N-Nitrosamines
April 25th 2025With increasing concern over genotoxic nitrosamine contaminants, regulatory bodies like the FDA and EMA have introduced strict guidelines following several high-profile drug recalls. This poster showcases a case study where LGC and Waters developed a UPLC/MS/MS method for quantifying trace levels of N-nitroso-sertraline in sertraline using Waters mass spectrometry and LGC reference standards.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
Using the Carcinogenic Potency Categorisation Approach (CPCA) to Classify N-nitrosamine Impurities
April 25th 2025Learn how to manage nitrosamine impurities in pharmaceuticals with our free infographic. Discover how the CPCA approach establishes acceptable intake limits and guides the selection of NDSRI reference samples. Stay compliant and ensure safety with our ISO-accredited standards.
